Higher Lipopolysaccharide Binding Protein and Chemerin Concentrations Were Associated with Metabolic Syndrome Features in Pediatric Subjects with Abdominal Obesity during a Lifestyle Intervention

Marti, Amelia; Martínez, Isabel; Ojeda‐Rodríguez, Ana; Azcona, Cristina

doi:10.3390/nu13020289

Cited by 14 publications

(9 citation statements)

References 35 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…( 25 ), including nearly one hundred obese children, confirmed that weight loss was associated with a decrease of chemerin levels and improvement of metabolic syndrome parameters such as insulin, HDL-C and TG. The associations between chemerin and weight loss were reported in several studies in obese pediatric and adult population ( 73 – 77 ). A study by Liu et al.…”

Section: Discussionmentioning

confidence: 83%

The link between vitamin D, chemerin and metabolic profile in overweight and obese children - preliminary results

et al. 2023

View full text Add to dashboard Cite

BackgroundVitamin D affects adipogenesis, oxidative stress, inflammation, secretion of adipocytokines, lipid metabolism and thermogenesis. Some researchers postulate that those effects could be exerted by the influence of vitamin D on chemerin levels.Aim of the studyWe aimed to investigate if there is a link between serum 25-hydroksyvitamin D [25(OH)D], chemerin and metabolic profile in overweight and obese children before and after vitamin D supplementation.Material and methodsThe prospective study included 65 overweight and obese children aged 9.08-17.5 years and 26 peers as a control. None of the patients in the study group had received vitamin D within the last twelve months before the study.ResultsThe study group had lower baseline 25(OH)D (p<0.001) and higher chemerin (p<0.001), triglycerides (TG, p<0.001), triglycerides/high density lipoprotein cholesterol (TG/HDL-C, p<0.001), C-reactive protein (CRP, p<0.05), fasting insulin (p<0.001), Homeostasis Model Assessment - Insulin Resistance (HOMA-IR, p<0.001), alanine aminotransferase (ALT, p<0.001) and uric acid (p<0.001) compared to the control group. Baseline vitamin D was related to fasting insulin (R=-0.29, p=0.021), HOMA-IR (R=-0.30, p=0.016), HDL-C (R=0.29, p=0.020) and uric acid (R=-0.28, p=0.037) in the study group. Baseline chemerin was related to insulin at 30’ (R=0.27, p=0.030), 60’ (R=0.27, p=0.033), 90’ (R=0.26, p=0.037) and 120’ (R=0.26, p=0.040) during the oral glucose tolerance test (OGTT) and ALT (R=0.25, p=0.041) in the study group. Correlation between vitamin D and chemerin (R=-0.39, p=0.046) was found only in the control group. After six months of vitamin D supplementation a decrease in CRP (p<0.01), total cholesterol (p<0.05), ALT (p<0.01), glucose at 150’ OGTT (p<0.05) was observed. Moreover, we noticed a tendency for negative association between 25(OH)D and chemerin levels (p=0.085). Multivariable backward linear regression models were build using baseline vitamin D, baseline chemerin and six months chemerin as the dependent variables.ConclusionsOur study confirmed that vitamin D has positive effect on metabolic profile in overweight and obese children. The relationship between vitamin D and chemerin is not clear, nevertheless we have observed a tendency to decrease chemerin concentrations after improving vitamin D status, even without a significant reduction in body fat mass.

show abstract

Section: Discussionmentioning

confidence: 83%

The link between vitamin D, chemerin and metabolic profile in overweight and obese children - preliminary results

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Reduced body weight has been found to improve intestinal conditions by restoring the selectivity of the intestinal barrier [ 182 , 183 ]. A moderate low-calorie diet together with increased physical activity after 2 and 12 months improved enteral permeability by decreasing chemerin and lipopolysaccharide-binding protein (LBP) levels in adolescents with abdominal obesity [ 184 ]. Assuming that body weight reduction can produce similar results regardless of the method used, metformin has been studied in a group of overweight or obese subjects in the “Survivorship Promotion In Reducing IGF-1 Trial” (SPIRIT) [ 185 ].…”

Section: Resultsmentioning

confidence: 99%

View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences

Froldi

2024

Pharmaceuticals

View full text Add to dashboard Cite

Metformin is a synthetic biguanide used as an antidiabetic drug in type 2 diabetes mellitus, achieved by studying the bioactive metabolites of Galega officinalis L. It is also used off-label for various other diseases, such as subclinical diabetes, obesity, polycystic ovary syndrome, etc. In addition, metformin is proposed as an add-on therapy for several conditions, including autoimmune diseases, neurodegenerative diseases, and cancer. Although metformin has been used for many decades, it is still the subject of many pharmacodynamic and pharmacokinetic studies in light of its extensive use. Metformin acts at the mitochondrial level by inhibiting the respiratory chain, thus increasing the AMP/ATP ratio and, subsequently, activating the AMP-activated protein kinase. However, several other mechanisms have been proposed, including binding to presenilin enhancer 2, increasing GLP1 release, and modification of microRNA expression. Regarding its pharmacokinetics, after oral administration, metformin is absorbed, distributed, and eliminated, mainly through the renal route, using transporters for cationic solutes, since it exists as an ionic molecule at physiological pH. In this review, particular consideration has been paid to literature data from the last 10 years, deepening the study of clinical trials inherent to new uses of metformin, the differences in effectiveness and safety observed between the sexes, and the unwanted side effects. For this last objective, metformin safety was also evaluated using both VigiBase and EudraVigilance, respectively, the WHO and European databases of the reported adverse drug reactions, to assess the extent of metformin side effects in real-life use.

show abstract

“…Our finding that behavioral weight loss reduces LBP is supported by several lines of evidence. Previous diet- or behavioral-induced weight loss interventions were also found to reduce LBP ( 8 , 14 , 20 ) or intestinal permeability assessed by lactulose:mannitol ratio. ( 13 ) In addition to behavioral weight loss, surgical weight loss has also been shown to reduce LBP, though LBP reduction may depend both on surgical method and timing of LBP measurement post-surgery.…”

Section: Discussionmentioning

confidence: 99%

“…However, weight lost through behavioral intervention or metformin treatment—current first-line treatments for obesity and diabetes, respectively—operate through different physiological mechanisms. ( 19 ) While a behavioral weight loss intervention has been shown to reduce LBP in adolescents with abdominal obesity,( 20 ) there have been no direct comparison between the effects of behavioral weight loss interventions and metformin on LBP in humans.…”

Section: Introductionmentioning

confidence: 99%

A behavioral weight-loss intervention, but not metformin, decreases a marker of gut barrier permeability: results from the SPIRIT randomized trial

et al. 2022

View full text Add to dashboard Cite

Background/Objectives: Lipopolysaccharide-binding protein (LBP), a biomarker of gut barrier permeability to lipopolysaccharides, is higher in adults with obesity and type 2 diabetes. Behavioral weight loss and metformin have distinct effects on the gut microbiome, but their impact on gut permeability to lipopolysaccharides is unknown. This study’s objective was to determine the effects of a behavioral weight loss intervention or metformin treatment on plasma LBP. Subjects/Methods: SPIRIT was a randomized trial of adults with overweight or obesity. Participants were randomized to one of three arms: metformin treatment, coach-directed behavioral weight loss on a DASH diet, or self-directed care (control). Of 121 participants, a random subset (n=88) was selected to have LBP measured at baseline, 6-months, and 12-months post intervention. Intervention effects on LBP over time were assessed using generalized estimating equations (GEE). We also examined whether the intervention effects were modified by change in diet and weight. Results: Arms were balanced by sex (83% female), race (51% white), and age (mean 60 years), with no differences in baseline LBP (median 4.23 μg/mL). At 1 year, mean weight change was −3.00% in the metformin arm, −3.02% in the coach-directed behavioral weight-loss arm, and +0.33% in the self-directed (control) arm. The corresponding change in LBP was +1.03, −0.98, +1.03 μg/mL. The behavioral weight-loss reduced LBP compared to self-directed care (β=−0.17, 95% CI: −0.33 to −0.01); no other between-arm comparisons were significant. Participants who reduced dietary fat showed the greatest reductions in 6-month LBP (β=−2.84, 95% CI: −5.17 to −0.50). Conclusions: Despite similar weight loss in the behavioral weight loss and metformin arms, only the behavioral weight loss intervention reduced LBP compared to control. Lifestyle weight loss interventions that promote a DASH diet may be effective at reducing gut barrier permeability to lipopolysaccharides.

show abstract

Higher Lipopolysaccharide Binding Protein and Chemerin Concentrations Were Associated with Metabolic Syndrome Features in Pediatric Subjects with Abdominal Obesity during a Lifestyle Intervention

Cited by 14 publications

References 35 publications

The link between vitamin D, chemerin and metabolic profile in overweight and obese children - preliminary results

The link between vitamin D, chemerin and metabolic profile in overweight and obese children - preliminary results

View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences

A behavioral weight-loss intervention, but not metformin, decreases a marker of gut barrier permeability: results from the SPIRIT randomized trial

Contact Info

Product

Resources

About